GPN Vaccines is a vaccine that is used to prevent the spread of streptococcus pneumoniae.
GPN Vaccines has raised $12.0M in total funding. The most recent round was Series B. The last funding was announced in June 2024.
GPN Vaccines's investors include Forepont Capital Partners, Shearwater Capital, National Health and Medical Research Council, Kern Whelan Capital, Government of South Australia.
GPN Vaccines is headquartered in Adelaide, Australia.
GPN Vaccines is a vaccine that is used to prevent the spread of streptococcus pneumoniae.
GPN Vaccines is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GPN Vaccines — Funding & Investors." VCBacked, June 6, 2024, https://www.vcbacked.co/company/gpn-vaccines. Accessed November 13, 2026.
VCBacked. (2024). GPN Vaccines — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/gpn-vaccines
{{cite web |title=GPN Vaccines — Funding & Investors |url=https://www.vcbacked.co/company/gpn-vaccines |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at GPN Vaccines? Request a listing update